Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia.

[1]  M. Poljak,et al.  Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. , 2013, Vaccine.

[2]  V. Kesic.  Prevention of cervical cancer in Central and Eastern Europe and Central Asia: a challenge for the future. , 2013, Vaccine.

[3]  J. Berkhof,et al.  Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. , 2013, Vaccine.

[4]  M. Poljak,et al.  Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. , 2013, Vaccine.

[5]  M. Poljak,et al.  Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. , 2013, Vaccine.

[6]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[7]  M. Poljak,et al.  Nucleic acid tests for the detection of alpha human papillomaviruses. , 2012, Vaccine.

[8]  J. Dillner,et al.  Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model , 2012, BMJ : British Medical Journal.

[9]  M Arbyn,et al.  Worldwide burden of cervical cancer in 2008. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Segnan,et al.  European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.